Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Adenosine Phosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 9/20 | 0.83 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.83 |
| ▸ | P2RY11 | Q96G91 | 3/20 | 0.83 |
| ▸ | SRC | P12931 | 2/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.83 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.83 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.83 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.83 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.83 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.83 |
| ▸ | LDHA | P00338 | 1/20 | 0.83 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.83 |
| ▸ | FBP1 | P09467 | 1/20 | 0.83 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.83 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.83 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.83 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.83 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.83 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine Phosphate SCHEMBL29574456 | 0.98 | P2RY1 (0.83) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL1416760 | 0.98 | P2RY1 (0.83) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL28252058 | 0.97 | P2RY1 (0.81) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL8425208 | 0.95 | P2RY1 (0.89) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL29724022 | 0.93 | P2RY1 (0.81) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL1164292 | 0.93 | P2RY1 (0.81) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Diphosphate SCHEMBL4406433 | 0.92 | P2RY1 (0.87) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Diphosphate SCHEMBL28284912 | 0.92 | P2RY1 (0.78) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL353218 | 0.92 | P2RY1 (0.83) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL1356934 | 0.92 | P2RY1 (0.83) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103744-A1 | CHIMERIC PRIMERS WITH HAIRPIN CONFORMATIONS AND METHODS OF USING SAME | LUMINEX CORPORATION (US) | 2026-04-16 | — | — | US | disclosed |
| US-12473586-B2 | Chimeric primers with hairpin conformations and methods of using same | LUMINEX CORPORATION (US) | 2025-11-18 | — | — | US | disclosed |
| US-20240318233-A1 | CHIMERIC PRIMERS WITH HAIRPIN CONFORMATIONS AND METHODS OF USING SAME | LUMINEX CORPORATION (US) | 2024-09-26 | — | — | US | disclosed |
| US-11884965-B2 | Chimeric primers with hairpin conformations and methods of using same | LUMINEX CORPORATION (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230295691-A1 | HIGHLY SPECIFIC CIRCULAR PROXIMITY LIGATION ASSAY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-09-21 | — | — | US | disclosed |
| US-11530438-B2 | Highly specific circular proximity ligation assay | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-12-20 | — | — | US | disclosed |
| US-20220251633-A1 | CHIMERIC PRIMERS WITH HAIRPIN CONFORMATIONS AND METHODS OF USING SAME | LUMINEX CORPORATION (US) | 2022-08-11 | — | — | US | disclosed |
| US-20220154180-A1 | PRODUCTION AND AMPLIFICATION OF NUCLEIC ACIDS | TOYOBO CO., LTD. (JP) | 2022-05-19 | — | — | US | disclosed |
| EP-3589750-B1 | HIGHLY SPECIFIC CIRCULAR PROXIMITY LIGATION ASSAY | UNIV LELAND STANFORD JUNIOR (US) | 2022-05-04 | — | — | EP | disclosed |
| US-11319577-B2 | Chimeric primers with hairpin conformations and methods of using same | LUMINEX CORPORATION (US) | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103744-A1 | CHIMERIC PRIMERS WITH HAIRPIN CONFORMATIONS AND METHODS OF USING SAME | MICA, RNGTT, DNMT3A | P2RY1 928/4885P2RY2 1194/4885P2RY11 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.